EGFR and gastric cancer: Furthermore, dual inhibition of MET and EGFR by “biseptic” antibodies, or combined inhibitors, demonstrated effective inhibition of tumor growth in vitro and in vivo (Castoldi et al., 2013; Lee et al., 2016a; Xu et al., 2011), in accord with our findings in GC cluster B. Recently, another dual inhibition of MET and EGFR in GC cells has emerged, based on inhibition of sphingosine 1-phosphate (S1P), a G protein-coupled receptor ligand (Shida et al., 2004).